Appropriate use of opioids for chronic pain in primary care
This promotional supplement has been commissioned and funded by Grünenthal and developed in partnership with Guidelines. Information intended for healthcare professionals only.
View PALEXIA® SR tablets (tapentadol hydrochloride) prescribing and adverse event reporting information
M-PLX-UK-10-21-0036 October 2021
Managing acne well—a summary of the 2021 NICE guideline
Information intended for UK healthcare professionals only. This promotional supplement has been commissioned and funded by Galderma and developed in partnership with Guidelines.
View Epiduo Gel 0.1% (0.1% adapalene & 2.5% benzoyl peroxide) prescribing information and adverse event reporting information.
View Epiduo Gel 0.3%/2.5 % (0.3% adapalene & 2.5% benzoyl peroxide) prescribing information and adverse event reporting information.
UKI-EDG-2100027
Date of preparation: October 2021
Prescribing hormone replacement therapy (HRT) in postmenopausal women: a focus on Oestrogel® (estradiol) and Utrogestan® 100 mg (micronised progesterone)
This prescribing supplement has been commissioned and funded by Besins Healthcare (UK) Ltd and developed in partnership with Guidelines. Includes promotional information.
View prescribing and adverse event reporting information
OES/2021/001a October 2021
For healthcare professionals only.
Recommending emollients for patients with atopic dermatitis or dry skin conditions
This supplement has been commissioned and funded by L’Oréal (UK) Limited and developed in partnership with Guidelines.
Date of preparation: January 2021
The importance of the progestogenic component of hormone replacement therapy in women with a uterus
Dr John Stevenson and Dr Sophia Tsiligiannis discuss progestogen prescribing in hormone replacement therapy.